Treatment for Severe Emphysema The vision of Pulmonx is to be a global leader in bronchoscopic treatment for emphysema. The Zephyr® Valve System has clinically-proven results, reliability, patient selection tools, and ease of use. Zephyr Valve How it Works Minimally Invasive Bronchoscopic Procedure...
Zephyr endobronchial valvecollateral ventilationpatient &lobar selectionIntroduction Emphysema affects millions of people in the United States; the underlying pathophysiology is destruction of lung parenchyma resulting in hyperinflation. To date mainstay of treatment is medical care however currently there are ...
REDWOOD CITY, Calif. – June 29, 2018–Pulmonx® Corp.announced today that the U.S. Food and Drug Administration (FDA) has approved the Zephyr® Endobronchial Valve System for treating severe emphysema patients. The Zephyr Valve is the first minimally-invasive device approved in the United S...
Zephyr® Valve: Treatment for Severe COPD/Emphysema Reducing Hyperinflation, an Underlying Cause of Breathlessness The majority of patients with advanced COPD/emphysema are treated with inhalers, medications and pulmonary rehabilitation. However, none of these treatments address the root cause of dyspnea...
emphysemasmokingbronchoscopylung volume reductionBackground Endobronchial valve (EBV) insertion for lung volume reduction is a management option for patients with severe emphysema. One‐way valves cause lobar deflation and improve lung function, exercise capacity and quality of life. Aims To retrospectively...
The Endobronchial Valve for Emphysema Palliation Trial (VENT) was a multi-centre, prospective, randomised, controlled trial conducted to evaluate the safety and effectiveness of unilateral endobronchial valve (EBV) treatment. The purpose of this analysis was to assess outcomes in the previously ...
Food and Drug Administration (FDA) has accepted Emphasys Medical's pre-market approval application for its Zephyr Endobronchial Valve (EBV) as suitable for filing and has granted it expedited review. The company claimed that the FDA decided to grant expedited review because of the potential of ...